About Kuros Biosciences Ltd. 
Kuros Biosciences Ltd.
Pharmaceuticals & Biotechnology
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Company Coordinates 
Company Details
Wagistrasse 25 , SCHLIEREN None : 8952
Registrar Details
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Management
Designation
Mr. Clemens van Blitterswijk
Chairman of the Board of Directors
Dr. Joost de Bruijn
Chief Executive Officer, Member of the Board of Directors
Ms. Leanna Caron
Vice Chairman of the Board of Directors
Dr. Scott Bruder
Member of the Board of Directors
Mr. Jason Hannon
Member of the Board of Directors
Mr. Oliver Walker
Member of the Board of Directors
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2013)
Net Profit:
-10 Million
Pharmaceuticals & Biotechnology
CHF 1,216 Million ()
NA (Loss Making)
NA
0.00%
-0.19
-40.21%
15.86






